Pulmatrix Q1 net loss $1.2M, cash $3.3M; merger with Eos SENOLYTIX set for Q3 2026

Pulmatrix, Inc.

2026-Q1 EPS reported -$0.32

Net loss $1.172M ($0.32/share) vs $1.808M ($0.50/share) in Q1 2025; no revenue reported.
Cash and equivalents $3.3M at March 31, 2026; going concern assumed through anticipated merger close.
Merger agreement with Eos SENOLYTIX signed March 26, 2026; expected close Q3 2026; common stock holders get ~6% of combined co.
Private placement of Series B convertible preferred stock from Eos affiliate raised $1.0M gross in March.
R&D expense <$0.1M; G&A down to $1.3M from $1.8M; clinical programs on hold pending out-license.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.